AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12357302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (80 mg/m²) in both feeding conditions
Number of subjects: 18
Study 12357302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (80 mg/m²)
Number of subjects: 18
Study 10550358 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol + Tazarotene (combined therapy)
Number of subjects: 50
Study 10550358 — intervention group
Group type: COMPARATOR
Intervention: Dithranol (monotherapy)
Number of subjects: 50
Study 7750526 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG, 81 mg
Number of subjects: 500
Study 7750526 — intervention group
Group type: COMPARATOR
Intervention: BCG, 27 mg
Number of subjects: 500
Study 10147031 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme
Number of subjects: 0
Study 10147031 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 6712861 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (single dose)
Number of subjects: 0
Study 6712861 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (single dose)
Number of subjects: 0
Study 6712861 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (chronic treatment for 28 days)
Number of subjects: 0
Study 6712861 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (chronic treatment for 28 days)
Number of subjects: 0
Study 6712861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 0
Study 31309919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) + n-3 fatty acids (2× 1000 mg/d from flaxseed oil)
Number of subjects: 61
Study 29695280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ekso™ gait training (EGT) (45-min/session, five times/week)
Number of subjects: 40
Study 26600191 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal stent (SX-ELLA Danis)
Number of subjects: 28
Study 26600191 — intervention group
Group type: COMPARATOR
Intervention: Balloon tamponade (Sengstaken-Blakemore tube)
Number of subjects: 28
Study 24951467 — intervention group
Group type: EXPERIMENTAL
Intervention: CloB2A2 regimen (clofarabine 30 mg/m(2)/day for 4 days, busulfan 3.2 mg/kg/day for 2 days, antithymocyte globulin 2.5 mg/kg/day for 2 days)
Number of subjects: 30
Study 24077218 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal SRMs
Number of subjects: 15
Study 24077218 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse SRMs
Number of subjects: 15
Study 24077218 — intervention group
Group type: COMPARATOR
Intervention: No SRMs
Number of subjects: 15
Study 24077218 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse speed reduction markings (TSRMs)
Number of subjects: 15
Study 22580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain saturated fatty acids (SFA)
Number of subjects: 34
Study 22580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 34
Study 22580729 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 34
Study 22580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain saturated fatty acids (SFA) and Monounsaturated fatty acids (MUFA)
Number of subjects: 34
Study 19101220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose caldaret
Number of subjects: 239
Study 19101220 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caldaret
Number of subjects: 239
Study 19101220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 17894265 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot training with MIT‐MANUS for shoulder and elbow, and novel distal wrist robot.
Number of subjects: 200
Study 17894265 — intervention group
Group type: COMPARATOR
Intervention: Control group of stroke survivors (40 participants).
Number of subjects: 200
Study 15472771 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 44
Study 15472771 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesic measures (Control)
Number of subjects: 44
Study 15472771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 11533423 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient held record
Number of subjects: 501
Study 11533423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient held record)
Number of subjects: 501
Study 9595866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress induction in migraine patients
Number of subjects: 23
Study 9595866 — intervention group
Group type: COMPARATOR
Intervention: Mental stress induction in tension headache patients
Number of subjects: 23
Study 9595866 — intervention group
Group type: COMPARATOR
Intervention: Mental stress induction in control group
Number of subjects: 23
Study 7778569 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care health plans (capitated payment)
Number of subjects: 387
Study 7778569 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service (FFS) plans
Number of subjects: 387
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 25 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 50 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 100 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.04 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.12 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.2 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1.0 mg
Number of subjects: 0
Study 2156887 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 7410324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TAD)
Number of subjects: 0
Study 7410324 — intervention group
Group type: COMPARATOR
Intervention: Other psychoactive drugs or placebo
Number of subjects: 0
Study 31895769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study 31722623 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND/PPMD Patient‐Centeredness Method (RPM)
Number of subjects: 122
Study 28803386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day (n=60)
Number of subjects: 190
Study 28803386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse at least three times a week (n=66)
Number of subjects: 190
Study 28803386 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (n=64)
Number of subjects: 190
Study 25602299 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg a day for 2 weeks
Number of subjects: 4373
Study 23603397 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropostural optimization (NPO)
Number of subjects: 31
Study 23603397 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 31
Study 21842454 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic shoes (intervention group)
Number of subjects: 220
Study 21842454 — intervention group
Group type: COMPARATOR
Intervention: No orthopedic treatment (control group)
Number of subjects: 220
Study 20082930 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min, 3 times/week for 3 months)
Number of subjects: 44
Study 20082930 — intervention group
Group type: COMPARATOR
Intervention: Control (relatively inactive)
Number of subjects: 44
Study 20082930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after crossover)
Number of subjects: 44
Study 17555465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (n = 30; dosed to maintain trough concentrations of 10‐25 ng ml(‐1) until week 8, and then 8‐15 ng ml(‐1) thereafter) in combination with daclizumab, oral MMF and corticosteroids
Number of subjects: 45
Study 17555465 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (CsA) (n = 15; administered as per centre practice) in combination with daclizumab, oral MMF and corticosteroids
Number of subjects: 45
Study 15104606 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of oral misoprostol
Number of subjects: 200
Study 15104606 — intervention group
Group type: COMPARATOR
Intervention: 3 mg prostaglandin E2 vaginal tablets
Number of subjects: 200
Study 11681540 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 81
Study 11681540 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere stimulation (rTMS)
Number of subjects: 81
Study 11681540 — intervention group
Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 81
Study 9010987 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 5 micrograms/kg
Number of subjects: 353
Study 9010987 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg
Number of subjects: 353
Study 9010987 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms/kg
Number of subjects: 353
Study 9010987 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 353
Study 9010987 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (combined doses)
Number of subjects: 353
Study 7944533 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral flucloxacillin
Number of subjects: 42
Study 7944533 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics when clinically indicated
Number of subjects: 42
Study 2178851 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (mean dose, 167 mg/day)
Number of subjects: 26
Study 2178851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 289417 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metronidazole (Flagyl) 200 mg every 8 hours for 3 days
Number of subjects: 100
Study 289417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 30805958 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-14 months multi-strategic intervention
Number of subjects: 70
Study 30805958 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 70
Study 27887885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a 'watching-eyes image' on a blood-donation flyer
Number of subjects: 454
Study 27887885 — intervention group
Group type: COMPARATOR
Intervention: Neutral picture on a blood-donation flyer (control condition)
Number of subjects: 454
Study 25851076 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic HbA1C orders for patients receiving chronic glucocorticoid
Number of subjects: 38
Study 25851076 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 38
Study 23808185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of mexidol 100 mg and picamilon 150 mg
Number of subjects: 94
Study 23808185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of mexidol 300 mg and picamilon 150 mg
Number of subjects: 94
Study 23808185 — intervention group
Group type: COMPARATOR
Intervention: Picamilon 150 mg
Number of subjects: 94
Study 21865944 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive glycemic control (90‐120 mg/dL)
Number of subjects: 82
Study 21865944 — intervention group
Group type: COMPARATOR
Intervention: Moderate glycemic control (120‐180 mg/dL)
Number of subjects: 82
Study 19442782 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg oral misoprostol
Number of subjects: 300
Study 19442782 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 300
Study 17141985 — intervention group
Group type: EXPERIMENTAL
Intervention: New amoxicillin/clavulanate therapeutic system (1500 mg amoxicillin and 125 mg clavulanic acid)
Number of subjects: 0
Study 17141985 — intervention group
Group type: COMPARATOR
Intervention: Regular immediate release amoxicillin/clavulanate formulation
Number of subjects: 0
Study 14732656 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 60 J/cm²
Number of subjects: 54
Study 14732656 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 120 J/cm²
Number of subjects: 54
Study 14732656 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT with 14 mg/m² infusion followed by red light exposure at 180 J/cm²
Number of subjects: 54
Study 14732656 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Number of subjects: 54
Study 11558864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam 3 g
Number of subjects: 180
Study 11558864 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g
Number of subjects: 180
Study 9491047 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching (n = 18)
Number of subjects: 43
Study 9491047 — intervention group
Group type: COMPARATOR
Intervention: Listening (n = 25)
Number of subjects: 43
Study 8192130 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 37
Study 8192130 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 37
Study 8192130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 8192130 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication
Number of subjects: 37
Study 3316371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment
Number of subjects: 0
Study 3316371 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31897548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (3-7 spheroids/cm2)
Number of subjects: 75
Study 31897548 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose (10-30 spheroids/cm2)
Number of subjects: 75
Study 31897548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (40-70 spheroids/cm2)
Number of subjects: 75
Study 31897548 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 75
Study 30132040 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic guidance (HG)
Number of subjects: 0
Study 30132040 — intervention group
Group type: EXPERIMENTAL
Intervention: Error amplification (EA)
Number of subjects: 0
Study 26680374 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme arginate (HA) 3 mg/kg
Number of subjects: 40
Study 26680374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 40
Study 25643127 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A injections
Number of subjects: 0
Study 25643127 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study 23905951 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral instrumentation
Number of subjects: 41
Study 23905951 — intervention group
Group type: COMPARATOR
Intervention: Bilateral instrumentation
Number of subjects: 41
Study 20608365 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangjing Decoction at the dose of 400 ml bid for 6 months
Number of subjects: 62
Study 20608365 — intervention group
Group type: COMPARATOR
Intervention: Yougui Capsules tid for 6 months
Number of subjects: 62
Study 18617746 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting a CAM practitioner
Number of subjects: 42277
Study 18617746 — intervention group
Group type: COMPARATOR
Intervention: Daily smoking of cigarettes
Number of subjects: 42277
Study 18617746 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total HADS-T score
Number of subjects: 42277
Study 18617746 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-level education
Number of subjects: 42277
Study 16854683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (10 mg)
Number of subjects: 7
Study 16854683 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7
Study 12803593 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (n = 53)
Number of subjects: 103
Study 12803593 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 5% ointment (n = 50)
Number of subjects: 103
Study 10789071 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized megestrol acetate tablet formulation
Number of subjects: 0
Study 10789071 — intervention group
Group type: COMPARATOR
Intervention: Conventional megestrol acetate formulation
Number of subjects: 0
Study 8851417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spin-echo sequence with flow compensation, respiratory triggering (RT), and 8 ETL
Number of subjects: 5
Study 8851417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spin-echo sequence with 16 ETL
Number of subjects: 5
Study 8851417 — intervention group
Group type: COMPARATOR
Intervention: Conventional spin-echo sequences with flow compensation and spatial presaturation
Number of subjects: 5
Study 1310916 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state mild hypothermia (rectal temperature 33.9 +/- 0.7 degrees C)
Number of subjects: 4
Study 1310916 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state mild hypothermia
Number of subjects: 4
Study 1310916 — intervention group
Group type: COMPARATOR
Intervention: Mild hypothermia
Number of subjects: 4
Study 1310916 — intervention group
Group type: COMPARATOR
Intervention: Heat exposure (ambient temperature 40 degrees C)
Number of subjects: 4
Study 6147293 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin at a dose of 250 micrograms/h in saline (n = 12)
Number of subjects: 22
Study 6147293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study 31524081 — intervention group
Group type: EXPERIMENTAL
Intervention: CH2 strain in single infection
Number of subjects: 106
Study 31524081 — intervention group
Group type: EXPERIMENTAL
Intervention: CH2 strain in mixed infection with EU strain
Number of subjects: 106
Study 31524081 — intervention group
Group type: COMPARATOR
Intervention: EU strain
Number of subjects: 106
Study 30075740 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer league (n=400)
Number of subjects: 1200
Study 30075740 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer league plus vocational training (n=400)
Number of subjects: 1200
Study 30075740 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=400)
Number of subjects: 1200
Study 27394978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10μg/h for 30min followed by 0.84μg/h for 72h)
Number of subjects: 91
Study 27394978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 27394978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 91
Study 24531238 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation interventions including consultation with a rehabilitation physician, pain management, physiotherapy, psychological treatment, and further specialist referrals
Number of subjects: 76
Study 24531238 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation interventions
Number of subjects: 76
Study 24531238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 21981661 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer pump time (mean 31.2 ± 7.9 h)
Number of subjects: 132
Study 21981661 — intervention group
Group type: COMPARATOR
Intervention: Shorter pump time (mean 22.7 ± 7.3 h)
Number of subjects: 132
Study 21981661 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer pump time
Number of subjects: 132
Study 19225466 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate for 6 months
Number of subjects: 237
Study 19225466 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 237
Study 19225466 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline testosterone level in the lowest tertile
Number of subjects: 237
Study 17462050 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrity-promoting care training programme for staff
Number of subjects: 33
Study 17462050 — intervention group
Group type: COMPARATOR
Intervention: Control ward (no intervention)
Number of subjects: 33
Study 16369194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) exercise training
Number of subjects: 15
Study 16369194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) exercise training
Number of subjects: 15
Study 11956118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 5569
Study 11956118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5569
Study 11956118 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 5569
Study 9605718 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 38
Study 9605718 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 7636819 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (5 minutes application)
Number of subjects: 0
Study 7636819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1% (injected subcutaneously)
Number of subjects: 0
Study 7636819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 0
Study 7636819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local anaesthetic)
Number of subjects: 0
Study 1968739 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (0.15 mg/Kg intravenous injection)
Number of subjects: 16
Study 1968739 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol during dobutamine infusion
Number of subjects: 16
Study 655186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 400 to 800 mg daily
Number of subjects: 40
Study 655186 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg daily (with 10 mg of amiloride or 50 mg of spironolactone)
Number of subjects: 40
Study 655186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 2000 mg for 48 hours (in-hospital evaluation)
Number of subjects: 40
Study 655186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (acebutolol and diuretics)
Number of subjects: 40
Study 30801994 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 23735
Study 30801994 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 23735